ViewMind

Precision brain health. To help prevent, diagnose and personalize treatment for brain disorders.

[ViewMind @ViewMind_]

Thanks Fox Business for featuring a short film, that will air nationally at about ViewMind Inc.#healthcare #technology #neurology #neuroscience #neurology #alzheimersdisease #MultipleSclerosis #biomarkers #neurodegenerativediseases #neurologicaldisorders #endalz

[ViewMind @ViewMind_]

🎉 ViewMind has graduated from the AgeTech Collaborative™ from AARP Accelerator Program!
We’re proud to be an AgeTech Collaborative™ Portfolio Company advancing innovation in cognitive health and longevity.
#agetech #AgeTechCollaborative #longevity #neurotech #digitalhealth

[ViewMind @ViewMind_]

Thank you to everyone who visited our stand and experienced ViewMind’s technology firsthand at the @alzassociation ’s International Conference in Toronto.

https://t.co/yRjxrgrMZT
#AAIC2025 #BrainHealth #Alzheimers #ClinicalTrials #DigitalBiomarkers #Innovation

[ViewMind @ViewMind_]

We’ve just presented one of our new studies at AAIC 2025: “Cognitive and Motor Behaviors in Alzheimer’s, Parkinson’s, and Healthy Individuals.”

Visit us at Booth #1437 to learn more about our cutting-edge cognitive assessment platform.
#AAIC2025
@alzassociation

[ViewMind @ViewMind_]

We’re presenting 3 scientific posters, including:
• Psychometric validation of ViewMind Atlas™ as a digital biomarker
• Comparison with traditional neuropsychological tests
• Cognitive & motor patterns in AD, Parkinson’s, and healthy individuals

[ViewMind @ViewMind_]

We are here at AAIC 2025
📍 Booth #1437 | 27 to 29 July 2025 | Toronto, Canada

We’re proud to be presenting cutting-edge research and showcasing our patented cognitive assessment platform, ViewMind Atlas™.
@alzassociation #AAIC2025 #BrainHealth #Alzheimers #HealthTech

[ViewMind @ViewMind_]

ViewMind Atlas™ is a non-invasive, eye-tracking-based digital tool that has the potential to support:
✔ Early detection of Alzheimer’s
✔ Cognitive endpoints in clinical trials
✔ Scalable integration into research and healthcare environments

[ViewMind @ViewMind_]

ALZHEIMER’S DRUG DISCOVERY FOUNDATION’S DIAGNOSTICS ACCELERATOR (DXA) Invests $1.4M in ViewMind’s technology. https://t.co/jvNuLA8wXW via @ein_news
#BrainHealth #Alzheimers #NeurologicalDisorders #HealthTech #EyeTracking #InnovationInHealthcare #Biomarkers #PrecisionMedicine

[ViewMind @ViewMind_]

We look forward to continued collaboration in 2025 as we keep pushing the boundaries of cognitive health assessments.
Thank you for being part of our journey.
Wishing you all a peaceful holiday season and a successful new year.

[ViewMind @ViewMind_]

As the year comes to a close, we want to take a moment to express our gratitude to our partners and supporters. Together, we advanced our mission of transforming brain health through innovative, data-driven solutions.
#BrainHealth #HealthInnovation #CognitiveHealth #ThankYou

[ViewMind @ViewMind_]

We appreciate the opportunity to contribute to discussions that drive innovation in brain health diagnostics.

[ViewMind @ViewMind_]

We are pleased to share that Dr. Danilo Verge, @ViewMind_ 's Chief Medical Officer, presented to nearly 300 endocrinologists at the Intensive @cursodavidson 2024 in Miami.

#ViewMind #MedicalEducation #CognitiveHealth #Endocrinology #DiagnosticsInnovation

[ViewMind @ViewMind_]

ViewMind’s non-invasive technology offers valuable insights that have the potential to also be relevant for endocrinologists. By detecting cognitive changes in cardiometabolic conditions, our solution has the potential to support earlier intervention and personalized care.

[ViewMind @ViewMind_]

"This advancement holds the potential to make a significant impact on healthcare. We are excited to participate in the landmark Bio-Hermes-002 study to validate our results,” said Mark Edwards, CEO & Co-founder of ViewMind Inc.

[ViewMind @ViewMind_]

ViewMind is proud to announce its participation in the Bio-Hermes-002 study in collaboration with the Global Alzheimer’s Platform Foundation® (GAP).

#BioHermes002 #AlzheimersResearch #DiversityInResearch #DigitalBiomarkers #ViewMind #Cognitive

[ViewMind @ViewMind_]

"In addition, ViewMind has developed a specialized assessment for Alzheimer’s disease. Initial results indicate high sensitivity and specificity to detect asymptomatic stages over 10 years before symptoms and amnestic MCI. ” said Mark Edwards, CEO & Co-founder of ViewMind Inc.

[ViewMind @ViewMind_]

@UKinArgentina A huge thank you to the #AccelerateUK team for this opportunity, and congratulations to all finalists

[ViewMind @ViewMind_]

We are honored to announce that ViewMind Inc. has been named one of the three winners of the Accelerate UK 2024 competition!

We are thrilled to be joining the #AccelerateUK program and look forward to the opportunities it will bring.

#innovation #BrainHealth #Health #healthcare

[ViewMind @ViewMind_]

@UKinArgentina Being selected as a winner underscores the global crisis in brain and mental health, highlighting the urgent need for solutions like ViewMind’s, which offers precise, rapid, scalable, and affordable brain health assessments.